Trial Profile

Optimizing Abiraterone (Zytiga) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Mar 2023 Results investigated whether changes in circulating tumor DNA (ctDNA) fraction during ARPI treatment are linked with mCRPC clinical outcomes by collecting Plasma cell-free DNA from NCT02426333;NCT02471469, published in the Clinical Cancer Research
07 Jun 2022 Pooled results from NCT02426333 and NCT02471469 studies presented at the 58th Annual Meeting of the American Society of Clinical Oncology
26 Aug 2021 Data from three clinical studies (ANDROPS, OPTIMUM(NCT02426333) and SNACK(NCT02883166)) assessing whether the exposure-respone relation for abiraterone is different for pre-chemotherapy patients compared to post-chemotherapy patients with mCRPC

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com